Investors and Media


RHEI Pharmaceuticals (RHEI) is a privately-held, specialty pharmaceutical company focused on bringing core, approved medicines from the U.S., Europe and Japan into the fast-growing Chinese marketplace. RHEI in-licenses approved and late stage pharmaceutical products and applies its development and regulatory expertise to bring these important therapies to China. RHEI’s internal capabilities encompass business development, regulatory approval and clinical development– combining a western approach to pharmaceuticals with Chinese professionals that are highly experienced in the region. RHEI has particular expertise in the areas of oncology, women’s health, infectious diseases and dermatology. RHEI applies its unique offering to branded pharmaceuticals through its close relationship with selected preferred commercial partners.